/
INDP
$3.06-$0.35 (-10.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$454.4M
133M shares
52-week range
$0.92 – $13.40
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
180.09%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-245.30
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $859.0K | $854.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$859.0K | −$854.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $35.4M | $26.7M | $2.7M | $2.5M | $6.3M | $7.6M | $7.3M | $9.3M |
| Operating income | −$43.3M | −$34.9M | −$3.6M | −$7.7M | −$14.9M | −$16.4M | −$15.4M | −$19.8M |
| EBITDA | −$42.6M | −$46.1M | −$3.6M | −$7.7M | −$14.3M | −$15.4M | −$15.0M | −$20.8M |
| Net income | −$43.5M | −$47.6M | −$3.6M | −$7.7M | −$14.3M | −$15.4M | −$15.0M | −$20.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -111.67 | -112.74 | -0.66 | -1.89 | -1.73 | -1.84 | -1.61 | -21.58 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-6.34 | $-6.34–$-6.34 | 1 |
| 2027 | $0 | $-4.42 | $-4.42–$-4.42 | 1 |
| 2028 | $42M | $0.79 | $0.79–$0.79 | 1 |
| 2029 | $123M | $6.40 | $6.40–$6.40 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$8.29
Price
$3.06
Implied upside
+171%
Peer comparison
Indaptus Therapeutics, Inc. Common Stock
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
www.indaptusrx.com- Employees
- 5
- IPO / List date
- Aug 4, 2021
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds INDP.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in INDP as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-27 | 1-for-28reverse |
| 2021-07-27 | 1-for-4reverse |
| 2020-10-30 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded INDP yet.
